Neuropathic pain associated with nucleoside reverse transcriptase inhibitors (NRTIs),
therapeutic agents for human immunodeficiency virus (HIV), responds poorly to available …

(−)-β-caryophyllene (BCP), a cannabinoid receptor type 2 (CB2)-selective
phytocannabinoid, has already been shown in precedent literature to exhibit both anti …

The widespread plant volatile beta-caryophyllene (BCP) was recently identified as a natural
selective agonist of the peripherally expressed cannabinoid receptor 2 (CB 2). It is found in …

Activation of cannabinoid CB2 receptors suppresses neuropathic pain induced by traumatic
nerve injury. The present studies were conducted to evaluate the efficacy of cannabinoid …

The purpose of this study was to evaluate if phytocannabinoids, synthetic cannabidiol
(CBD), and tetrahydrocannabivarin (THCV), and their combination, could protect mice from …

HIV remains a major burden to the health care system and neuropathic pain is the most
common neurological complication of HIV infection. Because current treatment strategies …

The incidence of chronic pain is high in the general population and it is closely related to
anxiety disorders, which promote negative effects on the quality of life. The cannabinoid …

Abstract CB2 cannabinoid receptors (CB2) are a promising therapeutic target that lacks
unwanted side effects of CB1 activation. However, the cell types expressing CB2 that …

Background: Chemotherapeutic agents produce dose-limiting peripheral neuropathy
through mechanisms that remain poorly understood. We previously showed that AM1710, a …

Despite management with opioids and other pain modifying therapies, neuropathic pain
continues to reduce the quality of life and daily functioning in HIV-infected individuals …